FDA approves plv-idiog\ (inav) for the treatment of adults with relapsed/refractory or refractory precursor B-cell acute lymphoblastic leukemia to treatment with anti-CD3/CD1CD19 bispecific immunoreactor teiber scrow intra subcuta